Specialty Medicine

Merck's Oral PCSK9 Inhibitor Approval Undercuts Injectables

Merck's Oral PCSK9 Inhibitor Approval Undercuts Injectables

George Padron
Specialty Medicine, Healthcare Headlines, FDA & Regulations, Cardiology, Access & Affordability, Prior Authorization, Managed Care, Formulary & Coverage, Pharmacy Benefit Trends | Jul 17, 2026
FDA approves Lipfendra (enlicitide), the first oral PCSK9 inhibitor, at $315 a month. Merck priced it under the injectables and moved PCSK9 into retail pharmacy.
Air Quality Alerts Blanket the Northeast as Canadian Smoke Pushes the AQI Into the Unhealthy Band

Air Quality Alerts Blanket the Northeast as Canadian Smoke Pushes the AQI Into the Unhealthy Band

George Padron
Specialty Medicine, Healthcare Headlines, Workforce & Practice, Pulmonology | Jul 16, 2026
Wildfire smoke drove Northeast air quality into the Unhealthy band Thursday. At AQI 151 to 200, the guidance covers everyone, and only KN95 or N95 masks help.
Medicare Advantage Star Measures Leave Kidney Care Gaps

Medicare Advantage Star Measures Leave Kidney Care Gaps

Sonia Reyes
Specialty Medicine, Healthcare Headlines, Policy & Legislation | Jul 15, 2026
An ASN committee review finds Medicare Advantage Star measures capture almost no guideline-directed kidney care, even as ESRD enrollment in MA now tops 50%.
Dr. Iris Kopeloff - Why Women's Skin Health Needs a Life-Stage Lens

Dr. Iris Kopeloff - Why Women's Skin Health Needs a Life-Stage Lens

Sonia Reyes
Viewpoints, Dermatology & Allergy | Jul 13, 2026
Dr. Iris Kopeloff of Organon discusses how hormonal transitions can shape inflammatory skin disease, treatment decisions, and the need for more individualized dermatologic care.
Two-Drug HIV Tablet Versus Standard First-Line Regimen in Phase 3 Trial

Two-Drug HIV Tablet Versus Standard First-Line Regimen in Phase 3 Trial

George Padron
Specialty Medicine, ID & Vaccines, Clinical Trial Updates | Jul 10, 2026
A phase 3 trial finds the two-drug doravirine-islatravir tablet noninferior to bictegravir-emtricitabine-tenofovir for initial HIV-1 treatment at 48 weeks.
Public Healthcare Costs Associated With Smoking in Hong Kong

Public Healthcare Costs Associated With Smoking in Hong Kong

George Padron
Specialty Medicine, Pulmonology, Managed Care, Population Health Management | Jul 9, 2026
A Hong Kong cohort of 1.57 million ties smoking to higher outpatient, emergency, and hospital costs, with women's cost multipliers exceeding men's.
Load More
Only Healthcare Today Covering Clinical Healthcare, Access and Cost

Only Healthcare Today
Covering Clinical Healthcare, Access and Cost

1 Hewitt Square, Suite 139
East Northport, NY 11731

Who We Are


About Us Editorial Policy Contributors & Partners

Connect


Contact Us Work With Us Advertising Terms of Use Privacy Policy